Short-term fundamentals remain pressured, but long-term catalysts like Medicare reimbursement and European expansion could drive valuation if commercial execution improves; monitor upcoming CDMO demand and inFoods® IBS adoption trends.
Price Chart
Executive Summary
Biomerica reported Q3 fiscal 2026 results with revenue down 11.6% YoY to $987K, driven by lower contract manufacturing, while net loss widened to $1.31M. Positive catalysts include CMS establishing a $300 Medicare reimbursement for inFoods® IBS, 45% YoY European revenue growth, and UK regulatory approval for hp+detect™, offset by declining top-line and gross margin compression.
Key Financial Metrics
Key Facts
- Q3 revenue declined 11.6% YoY to $987K from $1.12M, primarily due to lower contract manufacturing and absence of prior-year distributor orders
- Gross margin dropped to -4% in Q3 2026 from 2% in prior year, reflecting unfavorable product mix and lower volume
- Operating expenses remained flat at $1.25M despite revenue decline, contributing to wider net loss of $1.31M vs $1.16M
- Nine-month net loss improved to $2.63M from $3.43M, with net loss per share improving 37% to $(0.92)
- CMS established $300 Medicare reimbursement rate for inFoods® IBS, effective Jan 1, 2026
- European revenue grew 45% YoY to $287K, with hp+detect™ receiving UK MHRA registration and first commercial European lab order secured
- R&D expenses down 24% YTD to $583K as company shifts from development to commercialization
Financial Impact
Revenue down $133K YoY, gross margin negative, operating loss expanded to $1.30M in quarter
Risk Factors
- Continuing revenue decline and negative gross margins threaten cash runway
- Forward-looking statements dominate narrative with limited near-term financial visibility
- Dependence on regulatory and reimbursement progress introduces execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272959 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | DEF 14A | $1.76 | awaiting T+20 | — | $1.71 (−2.84%) |
Oct 15, 2026 12d ago | 8-K | $1.85 | awaiting T+20 | — | $1.71 (−7.57%) |
Oct 8, 2026 19d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.71 (−9.52%) |
Oct 8, 2026 19d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.71 (−9.52%) |
Sep 25, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.71 (+26.29%) |
Sep 24, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.71 (+26.29%) |
Sep 1, 2026 8w ago | Press Release | $2.09 $2.26 | ▲ +8.13% | ▲ +7.82% | $1.71 (−18.18%) |
Aug 27, 2026 8w ago | Insider Cluster | $2.14 $2.39 | ▲ +11.68% | ▲ +12.16% | $1.71 (−20.09%) |
Aug 26, 2026 8w ago | 8-K | $2.10 $2.40 | ▼ −14.29% | ▼ −14.39% | $1.71 (+18.57%) |
Jun 4, 2026 20w ago | 8-K | $2.12 $1.73 | ▼ −18.40% | ▼ −20.26% | $1.71 (−19.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers